Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, August 2001, p. 2403-2404, Vol. 45, No. 8
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.8.2403-2404.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
LETTERS TO THE EDITOR
In Vitro Activities of Mitomycin C against Growing and
Hypoxic Dormant Tubercle Bacilli
 |
LETTER |
Persistence of Mycobacterium tuberculosis infection
despite prolonged chemotherapy is a major problem in tuberculosis
control (3). Hypoxic dormant bacilli are, in contrast to
oxic replicating organisms, not effectively killed by conventional
antimycobacterials and could be one of the factors contributing to the
persistence (1). Metronidazole (7),
nitrofurantoin (4), and PA-824 (a nitroimidazopyran)
(5) are the first leads that show activity against dormant
bacteria. The compounds appear to act as prodrugs that require
reduction of their nitro group to reactive intermediates that then
cause damage and death of the bacilli. The finding that prodrugs that
require reduction to unfold their antimicrobial activity are effective
against hypoxic dormant bacilli prompted us to question whether
mitomycin C might possess antidormancy activity. This drug is used in
the chemotherapy of hypoxic solid tumours and requires reduction to
become biologically active (6). Here, we report the
analysis of the antimicrobial activity of mitomycin C on growing and
dormant Mycobacterium bovis BCG Pasteur ATCC 35734. Mitomycin C showed an MIC (4) of 5 nM (1.7 ng/ml). In
agreement with our previous report, a 104-fold-higher MIC
(50 µM) of nitrofurantoin was observed and metronidazole did not show
inhibition of growth (MIC of metronidazole > 1,000 µM)
(4). Figure 1A shows that
mitomycin C at MIC appears to be bacteriostatic. Incubation of growing
cultures with 10 times the MIC of mitomycin C (50 nM) resulted in a
104-fold decrease in viability after 5 days. To grow
dormant organisms, we employed the Wayne dormancy culture system.
Wayne's model is based on growth of the bacilli in sealed tubes with
stirring. Initially the cultures grow exponentially and consume oxygen. A temporal oxygen gradient is generated, and when oxygen is depleted the cultures enter stationary phase. The hypoxic stationary-phase bacteria do not replicate but maintain viability; they are in a state
of dormancy (2, 8). Figure 1B shows that exposure of
dormant bacilli to 500 nM mitomycin C resulted in a 30-fold reduction
in viable counts after 5 days. To achieve a kill that was similar to
that observed for mitomycin C, a 1,000-fold higher concentration of
nitrofurantoin was required: 500 µM nitrofurantoin reduced viability
of the dormant culture 90-fold after exposure for 5 days, while 500 µM metronidazole reduced viability of the oxygen-starved culture only
2-fold after exposure for 5 days (4). Comparison of the
activities of mitomycin C against growing (Fig. 1A) and dormant (Fig.
1B) cultures shows that the growing bacilli were more sensitive to the
drug. Furthermore, it is interesting to note the difference in the
exposure time-kill curves for growing and dormant cultures. Growing
cultures were killed (as expected) in an exposure time-dependent
fashion. In contrast hypoxic cultures appear to lose viability rapidly
10-fold, and then the CFU level off. Whether this indicates the
presence of a mitomycin C-resistant subpopulation in the dormant
culture remains to be elucidated.

View larger version (28K):
[in this window]
[in a new window]
|
FIG. 1.
Effects of mitomycin C (MMC) on the viability of oxic
growing (A) and hypoxic dormant (B) BCG cultures. CFU were measured by
plating and colony counting. The experiments were carried out two times
with duplicate cultures exactly as described previously
(4). Mean values and standard deviations are shown. MMC
(Roche) stock solution was prepared in water. Significant clumping or
pH changes were not observed. Drug-containing dormant cultures were
diluted at least 103-fold before the plating. Thus,
dilutions of dormant cultures contained less than 10% of the MIC.
However, determination of survival of growing cultures exposed to the
maximum mitomycin C concentration used (50 nM) required plating of
undiluted culture samples on days 4 and 5. To directly examine possible
drug carryover effects, culture was diluted in broth containing 50 nM
mitomycin C and plated immediately together with drug-free controls.
CFU of drug-containing and drug-free samples were similar,
demonstrating that drug carryover effects were negligible.
|
|
In conclusion, the comparison of the effects of mitomycin C and the
nitroheterocyclic drugs on dormant bacilli revealed that mitomycin C
showed activity at a 1,000-fold-lower concentration. Furthermore,
mitomycin C showed a drastically lower MIC.
 |
ACKNOWLEDGMENTS |
We thank Marianne Eleuterio for discussion.
This study was supported by the Institute of Molecular and Cell Biology (IMCB).
 |
FOOTNOTES |
*
Phone: (65)
8748606 Fax: (65) 7791117 E-mail: mcbtd{at}imcb.nus.edu.sg
 |
REFERENCES |
| 1.
|
Dick, T.
2001.
Dormant tubercle bacilli: the key to more effective TB chemotherapy?
J. Antimicrob. Chemother.
47:117-118[Free Full Text].
|
| 2.
|
Lim, A.,
M. Eleuterio,
B. Hutter,
B. Murugasu-Oei, and T. Dick.
1999.
Oxygen depletion induced dormancy in Mycobacterium bovis BCG.
J. Bacteriol.
181:2252-2256[Abstract/Free Full Text].
|
| 3.
|
Manabe, Y. C., and W. R. Bishai.
2000.
Latent Mycobacterium tuberculosis persistence, patience, and winning by waiting.
Nat. Med.
6:1327-1329[CrossRef][Medline].
|
| 4.
|
Murugasu-Oei, B., and T. Dick.
2000.
Bactericidal activity of nitrofurans against growing and dormant Mycobacterium bovis BCG.
J. Antimicrob. Chemother.
46:917-919[Abstract/Free Full Text].
|
| 5.
|
Stover, C. K.,
P. Warrener,
D. R. Vandevanter,
D. R. Sherman,
T. M. Arain,
M. H. Langhorne, et al.
2000.
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis.
Nature
405:962-966[CrossRef][Medline].
|
| 6.
|
Tomasz, M., and Y. Palom.
1997.
The mitomycin bioreductive antitumor agents: cross-linking and alkylation of DNA as the molecular basis of their activity.
Phamacol. Ther.
76:73-87.
|
| 7.
|
Wayne, L. G., and H. A. Sramek.
1994.
Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis.
Antimicrob. Agents Chemother.
38:2054-2058[Abstract/Free Full Text].
|
| 8.
|
Wayne, L. G., and L. G. Hayes.
1996.
An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence.
Infect. Immun.
64:2062-2069[Abstract].
|
| | | | |
H. L. Peh
A. Toh
B. Murugasu-Oei
T. Dick*
Institute of Molecular and Cell Biology Singapore 117609, Singapore
|
Antimicrobial Agents and Chemotherapy, August 2001, p. 2403-2404, Vol. 45, No. 8
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.8.2403-2404.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Lee, J.-H., Geiman, D. E., Bishai, W. R.
(2008). Role of Stress Response Sigma Factor SigG in Mycobacterium tuberculosis. J. Bacteriol.
190: 1128-1133
[Abstract]
[Full Text]
-
Warner, D. F., Mizrahi, V.
(2006). Tuberculosis Chemotherapy: the Influence of Bacillary Stress and Damage Response Pathways on Drug Efficacy. Clin. Microbiol. Rev.
19: 558-570
[Abstract]
[Full Text]
-
Voskuil, M. I., Schnappinger, D., Visconti, K. C., Harrell, M. I., Dolganov, G. M., Sherman, D. R., Schoolnik, G. K.
(2003). Inhibition of Respiration by Nitric Oxide Induces a Mycobacterium tuberculosis Dormancy Program. JEM
198: 705-713
[Abstract]
[Full Text]
-
Boon, C., Dick, T.
(2002). Mycobacterium bovis BCG Response Regulator Essential for Hypoxic Dormancy. J. Bacteriol.
184: 6760-6767
[Abstract]
[Full Text]